Topics:
Hematologic Malignancies • Pediatric Oncology • Medical Oncology • Lymphoma • Hematology • Pediatric Hematology • ASH 2021
How will you use Pola-R-CHP in the frontline treatment of DLBCL?
Given the POLARIX study data presented at ASH 2021, will this replace R-CHOP as the standard of care therapy in your practice? If not, how will you utilize this regimen (if at all)?
Answer from: Medical Oncologist at Academic Institution
Given the comparable toxicity profile and the lower rate of treatment failure, the number needed to treat (n=16) is low enough that this is very appropriate to be the new standard of care. Although overall survival was not different, fewer patients treated with the Pola-R-CHP required subsequent tre...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
PFS benefit of around 7% (HR-0.73) and perhaps beneficial in DLBCL with higher IPI. Not clear that everyone is going to benefit from CHP-Pola. Would pay closer attention to details of neuropathy even though they were reportedly similar.